Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Karyopharm Therapeutics Inc.

Get SEC filing alerts via email and in your feed for Karyopharm Therapeutics Inc.

KPTI

Karyopharm Therapeutics Inc.

About Karyopharm Therapeutics Inc.

Karyopharm Therapeutics develops novel cancer therapies targeting nuclear export, primarily through its oral XPO1 inhibitors like XPOVIO (selinexor). The company focuses on hematological malignancies such as multiple myeloma, myelofibrosis, and diffuse large B-cell lymphoma, as well as solid tumors like endometrial cancer. Its business model combines drug discovery, clinical development, and global commercialization, leveraging strategic partnerships to address high unmet medical needs with first-in-class, mechanism-based treatments.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Karyopharm Therapeutics Inc.

1
1
Karyopharm Therapeutics Inc. Karyopharm Therapeutics Reports 17% Revenue Growth to $35.1 Million in Q1 2026

Via official filing (AI summary) | 30 days ago | 0 comments

2
1
Karyopharm Therapeutics Inc. Karyopharm Therapeutics Reports $196M Net Loss and Slight Revenue Increase for 2025

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
Karyopharm Therapeutics Inc. Karyopharm Therapeutics Reports 14% Revenue Growth in Q3 2025 Amid Increased Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Karyopharm Therapeutics Inc. Karyopharm Therapeutics Reports $37.9M Revenue in Q2 2025, Faces Financial Challenges

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Karyopharm Therapeutics Inc. Karyopharm Therapeutics Reports Q1 2025 Financial Results with $30M Revenue Decline

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Karyopharm Therapeutics Inc. Karyopharm Therapeutics Reports $76.4M Net Loss and $145.2M Revenue for 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Karyopharm Therapeutics Inc. Karyopharm Therapeutics Reports Mixed Q3 2024 Results, Ongoing Challenges in Profitability

Via official filing (AI summary) | over 1 year ago | 0 comments